Table 2.

Baseline Characteristics of Patients

	HBeAg-positive patients	HBeAg-negative patients	Overall group	P value
Number of patients	44	190	234
Age, years	29 (18–45)	39 (19–82)	35 (18–82)	<0.001
Age distribution, n (%)				<0.001
≥40	2 (4.5)	90 (47.4)	92 (39.3)
Gender, n (%)				0.03
Male	14 (31.8)	108 (56.8)	122 (52.1)
Race, n (%)				0.009
Caucasian	2 (4.6)	35 (18.4)	37 (15.8)
Asian	40 (90.8)	129 (76.3)	169 (72.2)
Other	2 (4.6)	26 (13.7)	28 (11.9)
BMI	23±4.5	25.1±5.4	24.7±5.3	0.031
Family history of HCC, n (%)				0.18
Positive	8 (18.2)	22 (11.6)	30 (12.8)
Negative	25 (56.8)	135 (71.1)	160 (68.4)
Unknown	11 (25)	33 (17.4)	44 (18.8)
Follow-up period, months	29.1 (12–158.7)	57.7 (12–163.8)	51 (12–163.8)	<0.001
Laboratory values
Platelet (k/mm3)	235±51	224±60	226±58	0.30
INR	0.98±0.09	0.99±0.07	0.99±0.07	0.60
Albumin (g/dL)	4.2±0.4	4.4±0.4	4.3±0.3	0.09
AST (U/L)	30±11	30±18	30±17	0.83
ALT (U/L)	37±17	39±22	39±21	0.50
ALT distribution, n (%)				0.48
<ULN	28 (63.6)	119 (62.6)	147 (62.8)
1–2X ULN	16 (36.4)	65 (34.2)	81 (34.6)
>2X ULN	0 (0)	6 (3.2)	6 (2.6)
HBV DNA, n (%)				<0.0001
<2,000 IU/mL	2 (4.5)	101 (53.2)	103 (44.1)
2,000–19,999 IU/mL	2 (4.5)	52 (27.9)	54 (23.1)
20,000–199,000 IU/mL	3 (6.8)	26 (13.7)	29 (12.4)
≥200,000 IU/mL	37 (84.1)	10 (5.3)	47 (20.1)
Liver histology, n	3	30	33
Ishak fibrosis score, n (%)				0.074
0–1	2 (66.7)	23 (76.6)	25 (75.7)
2–3	1 (33.3)	7 (23.4)	8 (24.3)
4–6	0 (0)	0 (0)	0(0)
REACH-B Score*, n	9	115	124	<0.001
Mean±SD	8.8±0.8	6.4±2.9	6.5±2.9

Results are expressed as number (%), mean±SD, median (range),

^*REACH-B score is applied to patients who had ≥3 years of follow-up.